1-3-18 8:37 AM EST | Email Article

By Adam Clark

 

Shire PLC (SHP.LN) said Wednesday that its Xiidra treatment for symptoms of dry eye disease has been approved in Canada, its first international approval outside the U.S.

The pharmaceutical company said the eye-drop solution is the first new prescription medication for dry eye disease to be approved by Canada in seven years, and will be available to patients in early 2018.

Shares were up 6.50 pence, or 0.2%, at 3,898.50 pence at 1319 GMT.

 

Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones

 

(END) Dow Jones Newswires

January 03, 2018 08:37 ET (13:37 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Add a Comment

Try Premium Membership today. Your first 14 days are free of charge. Start my Premium Membership Trial.
Sponsored Links
Buy a Link Now
Sponsor Center
Content Partners